A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.

NCT07284173 | Active Not Recruiting Phase 1

• 1 other identifier: C6231005
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 2

Brief Summary

This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves. The study will take in healthy adult participants aged 18 to 65 years who are not able to have children. Eligible participants must weigh more than 50 kilograms (110 pounds) and have a Body Mass Index (BMI) between 18.5 and 27.9. Each participant will receive two treatments:

• One treatment with PF-08049820 alone
• One treatment with PF-08049820 taken together with rabeprazole Both medicines will be taken by mouth. Participants will stay at the study clinic for a few days during each treatment period. During these stays, the study team will collect blood samples to see how the body absorbs and processes the medicine.

Conditions

Healthy Adults

Keywords

Healthy; Atopic Dermatitis

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08049820.

  Day 1 through Day 38-45

• PK: Area under the plasma concentration (AUC) of PF-08049820

  Day 1 through Day 38-45

Secondary Outcomes (1)

• Number of participants with treatment emergent adverse events

  First dose through Day 38-45

Study Arms (2)

Treatment A

EXPERIMENTAL

Participants will receive single oral dose of PF-08049820.

Drug: PF-08049820

Treatment B

EXPERIMENTAL

Participants will receive rabeprazole for 5 days followed by a single oral dose of PF-08049820 and rabeprazole.

Drug: PF-08049820; Drug: Rabeprazole

Interventions

PF-08049820 DRUG

Oral tablets

Treatment A; Treatment B

Rabeprazole DRUG

Oral tablets

Also known as: Pariet

Treatment B

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female participants of non-childbearing potential aged 18 to 65 years, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12-lead electrocardiogram.
• BMI of 18.5-27.9 kg/m2; and a total body weight \>50 kg (110 lb).
• Participants who are willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.

You may not qualify if:

• History or evidence of significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic diseases.
• Positive test for HIV, hepatitis B (HBsAg), or hepatitis C (HCVAb).
• Active or latent tuberculosis (TB) infection or inadequate treatment history for TB.
• Any medical or psychiatric condition, including active suicidal ideation in the past year or suicidal behavior in the past 5 years, that may increase risk or interfere with study participation.
• Current use of prohibited medications or inability/unwillingness to use required medications.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (2)

Beijing Friendship Hospital Affiliate of Capital University

Beijing, Beijing Municipality, 100050, China

Location

Beijing Friendship Hospital Affiliate of Capital University

Beijing, Beijing Municipality, 101100, China

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Dermatitis, Atopic

Interventions

Rabeprazole

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 13, 2025
• First Posted: December 16, 2025
• Study Start: November 3, 2025
• Primary Completion: December 15, 2025
• Study Completion: December 15, 2025
• Last Updated: December 16, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)